# Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

> **NCT02724904** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Lymphoma

## Interventions

- **PROCEDURE:** Allogeneic stem cell transplantation
- **DRUG:** Fludarabine
- **DRUG:** Thiotepa
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02724904
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05
- **Primary completion:** 2019-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug logistics
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724904, "Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02724904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*